The Value of ctDNA on Chemotherapy Efficacy for mCRC

Fudan University300 enrolled

Overview

The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

300

Conditions

Circulating Tumor DNA

Interventions

ct-DNAGENETIC

The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status of 0 to 2 life expectancy of ≥ 3 months at least one measurable metastatic lesion have adequate bone marrow, hepatic, and renal function Exclusion Criteria: patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Response rate

the response rate predicted by ct-DNA

Time frame: 2 months

Secondary Outcomes

Progression free survival

Time frame: 2 months

Overall survival

Time frame: 2 months

Central Contacts

Weijian Guo, phD

CONTACT

8621-64175590 iamchangjinjia@163.com

Weijian Guo

CONTACT

8621-64175590 iamchangjinjia@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.